Scarica l'app Stockscreener
0.7955
1.13%
-0.0055
Precedente Chiudi:
$0.79
Aprire:
$0.7974
Volume 24 ore:
10,941
Relative Volume:
0.01
Capitalizzazione di mercato:
$25.20M
Reddito:
$1.22M
Utile/perdita netta:
$-22.43M
Rapporto P/E:
-0.6879
EPS:
-1.1564
Flusso di cassa netto:
$-18.78M
1 W Prestazione:
+1.09%
1M Prestazione:
+16.50%
6M Prestazione:
+41.30%
1 anno Prestazione:
-39.45%
Intervallo 1D:
$0.7811
$0.7974
Intervallo di 1 settimana:
$0.7536
$0.82
Portata 52W:
$0.475
$1.80
Longeveron Inc Stock (LGVN) Company Profile
Nome
Longeveron Inc
Settore
Industria
Telefono
305-302-7158
Indirizzo
1951 NW 7TH AVENUE, MIAMI
Compare LGVN vs VRTX, REGN, ARGX, ALNY, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LGVN
Longeveron Inc
|
0.7974 | 24.96M | 1.22M | -22.43M | -18.78M | -1.1564 |
VRTX
Vertex Pharmaceuticals Inc
|
450.39 | 114.33B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
611.72 | 64.47B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
875.97 | 54.99B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
278.58 | 38.42B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
157.13 | 34.03B | 742.00K | -1.37B | -1.07B | -7.0731 |
Longeveron Inc Stock (LGVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-06 | Iniziato | ROTH MKM | Buy |
Longeveron Inc Borsa (LGVN) Ultime notizie
Longeveron receives SME status from European regulator By Investing.com - Investing.com Nigeria
Longeveron receives SME status from European regulator - Investing.com UK
Longeveron Granted SME Status by European Medicines Agency - Moomoo
Longeveron Inc. Awarded SME Status by European Medicines Agency, Enhancing Drug Development Opportunities - Quiver Quantitative
Biotech Longeveron wins EMA SME status, where SME drugs saw 89% OKs - Stock Titan
LGVN Shares Rise After Investigational Therapy Shows Improvement In Age-Related Frailty Study - Stocktwits
Number of shareholders of Longeveron Inc. – BOATS:LGVN - TradingView
LGVN Q1 2026 Earnings: Deeper Losses Weigh on Shares as Clinical Progress ContinuesGross Profit Margin - newsline.com
Longeveron Announces CFO Transition to Internal Successor - TipRanks
LongeveronOn June 1, Lisa Locklear To Step Down As CFO Effective July 10, 2026SEC Filing - TradingView
Longeveron (NASDAQ: LGVN) CFO Lisa Locklear to step down, controller eyed as successor - Stock Titan
Longeveron to Present at BIO International Convention 2026 - BioSpace
Stem cell firm Longeveron seeks Alzheimer’s, heart partners at BIO 2026 - Stock Titan
LGVN Q1 2026 Earnings: EPS Misses Estimates as Clinical-Stage Biotech Continues R&D AdvancesShare Repurchase Impact - newsline.com
LGVN Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Clinical-Stage Biotech Navigates Costs - newsline.com
Longeveron Inc. (LGVN) Q1 2026 Earnings: Wider-Than-Expected Loss Pressures SharesEarnings Trend Analysis - The Legal Advocate
Longeveron Inc. (LGVN) Extends Decline: Tests Key Support at $0.74 After 4.9% DropDebt Free Companies - newsline.com
Longeveron (LGVN) Stock Forecast & Analyst Ratings - Moomoo
Longeveron Inc. Q1 2026 Earnings: EPS Misses Estimates Despite Stock RallyAdjusted Earnings Analysis - newsline.com
LGVN stock slips after hours as FDA flags concerns on rare heart defect trial design - MSN
LGVN Should I Buy - Intellectia AI
Longeveron CEO outlines strategy ahead of August trial data - Investing.com India
Longeveron CEO outlines strategy ahead of August trial data By Investing.com - Investing.com Nigeria
Longeveron Inc. (LGVN) Edges Higher Amid Stabilization at $0.72Dividend Growth Stocks - The Legal Advocate
[ARS] Longeveron Inc. SEC Filing - Stock Titan
Longeveron (NASDAQ: LGVN) plans reverse split, bigger share pool and incentive plan - Stock Titan
Longeveron Issues Letter to Stockholders Highlighting Corporate Strategy, Strategic Partnering ... - Caledonian Record
Longeveron Issues Letter to Stockholders Highlighting - GlobeNewswire
Longeveron anticipates August 2026 ELPIS II readout while shifting to an asset-light partnering model - MSN
Earnings call transcript: Longeveron Q1 2026 reveals strategic shift By Investing.com - Investing.com Nigeria
Earnings call transcript: Longeveron Q1 2026 reveals strategic shift - Investing.com
[SCHEDULE 13G] Longeveron Inc. Passive Investment Disclosure (>5%) - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Longeveron Earnings Call: Trial Milestones Amid FDA Hurdles - TipRanks
Longeveron Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Longeveron Inc Azioni (LGVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.61%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):